Publication | Open Access
Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy
16
Citations
39
References
2023
Year
The assay allows for sensitive disease detection of B-ALL MRD independent of CD19 and CD22 expression and allows uniform analysis of samples regardless of anti-CD19 and CD22 therapy.
| Year | Citations | |
|---|---|---|
Page 1
Page 1